A Phase I Study of Oral BGJ398 in Asian Patients
A Phase I Study of Oral BGJ398 in Asian Patients With Advanced Solid Tumor Having Alterations of the FGF-R Pathway
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Gedetailleerde beschrijving
Studietype
Studietype
Inschrijving (Werkelijk)
Inschrijving
Fase
Fase
- Fase 1
Contacten en locaties
Studie Locaties
-
-
-
Guangzhou, China, 510060
- Novartis Investigative Site
-
-
Guangdong
-
Guangzhou, Guangdong, China, 51000
- Novartis Investigative Site
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Novartis Investigative Site
-
-
-
-
Aichi
-
Nagoya-city, Aichi, Japan, 466-8560
- Nagoya University Hospital
-
-
Chiba
-
Kashiwa, Chiba, Japan, 277-8577
- National Cancer Center Hospital East (NCEE)
-
-
Hyogo
-
Kobe-shi, Hyogo, Japan, 650-0017
- Novartis Investigative Site
-
-
Osaka
-
Sayama, Osaka, Japan, 589 8511
- Novartis Investigative Site
-
-
Shizuoka
-
Sunto-gun, Shizuoka, Japan, 411-8777
- Shizuoka Cancer Center
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Patients with advanced solid tumors with FGF-R alteration
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Adequate organ function
Exclusion Criteria:
- Patients with untreated and/or symptomatic metastatic Central Nerve System (CNS) disease
- Pregnant or nursing (lactating) women
Other protocol-defined inclusion/exclusion criteria may apply.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: BGJ398
Eligible participants received oral BGJ398 once daily or twice daily.
Patients may continue treatment with BGJ398 until the patient experiences unacceptable toxicity or progressive disease.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Incidence rate and category of dose limiting toxicities (DLTs)
Tijdsspanne: First cycle of 28 days
|
Maximum tolerated dose (MTD) and/or Recommended dose (RD) of single agent oral BGJ398
|
First cycle of 28 days
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Frequency of all Adverse Events (AEs) and Serious Advers Events (SAEs)
Tijdsspanne: From within 21 days of first treatment to 28 days after treatment discontinuation
|
To characterize the safety and tolerability of oral BGJ398
|
From within 21 days of first treatment to 28 days after treatment discontinuation
|
|
Changes in hematology and chemistry values
Tijdsspanne: From baseline to 28 days after treatment discontinuation
|
hematology and chemistry values
|
From baseline to 28 days after treatment discontinuation
|
|
Assessments of physical examinations, vital signs and electrocardiograms (ECGs)
Tijdsspanne: Participants will be followed for the duration of treatment, an expected average of 24 weeks.
|
Participants will be followed for the duration of treatment, an expected average of 24 weeks.
|
|
|
Time vs. concentration profiles
Tijdsspanne: 1 to 10 time points (0, 0.25, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose) up to 24 weeks
|
To determine the pharmacokinetic (PK) profiles (Cmax, AUC, Tmax, T1/2, etc) of oral BGJ398 including known pharmacologically active metabolites
|
1 to 10 time points (0, 0.25, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose) up to 24 weeks
|
|
Preliminary anti-tumor activity
Tijdsspanne: Participants will be followed for the duration of treatment, an expected average of 24 weeks.
|
Assessed based on RECIST version 1.1
|
Participants will be followed for the duration of treatment, an expected average of 24 weeks.
|
|
Best overall response (BOR)
Tijdsspanne: Participants will be followed for the duration of treatment, an expected average of 24 weeks.
|
Assessed by investigator per RECIST version 1.1.
BOR is the best response recorded until disease progression.
|
Participants will be followed for the duration of treatment, an expected average of 24 weeks.
|
|
Overall response rate (ORR)
Tijdsspanne: Participants will be followed for the duration of treatment, an expected average of 24 weeks.
|
Assessed by investigator per RECIST version 1.1.
ORR is the proportion of patients with a best overall response of Complete Response (CR) or Partial Response (PR).
|
Participants will be followed for the duration of treatment, an expected average of 24 weeks.
|
|
Progression-free survival (PFS)
Tijdsspanne: From date of end of treatment until the date of progression, or date of death, or starting date of a new anticancer therapy, assessed up to 100 months.
|
PFS is defined as the times from the date of first dose of BGJ398 to the date of the first documented disease progression, date of death due to any cause or until a new anticancer therapy is initiated, whichever occurs first.
|
From date of end of treatment until the date of progression, or date of death, or starting date of a new anticancer therapy, assessed up to 100 months.
|
|
Duration of all Adverse Events (AEs)
Tijdsspanne: From within 21 days of first treatment to 28 days after treatment discontinuation
|
To characterize the safety and tolerability of oral BGJ398
|
From within 21 days of first treatment to 28 days after treatment discontinuation
|
|
Duration of Serious Advers Events (SAEs)
Tijdsspanne: From within 21 days of first treatment to 28 days after treatment discontinuation
|
To characterize the safety and tolerability of oral BGJ398
|
From within 21 days of first treatment to 28 days after treatment discontinuation
|
|
Severity of all Adverse Events (AEs)
Tijdsspanne: From within 21 days of first treatment to 28 days after treatment discontinuation
|
To characterize the safety and tolerability of oral BGJ398
|
From within 21 days of first treatment to 28 days after treatment discontinuation
|
|
Severity of all Serious Advers Events (SAEs)
Tijdsspanne: From within 21 days of first treatment to 28 days after treatment discontinuation
|
To characterize the safety and tolerability of oral BGJ398
|
From within 21 days of first treatment to 28 days after treatment discontinuation
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Studie start
Primaire voltooiing (Werkelijk)
Primaire voltooiing
Studie voltooiing (Werkelijk)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
Andere studie-ID-nummers
- CBGJ398X1101
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .